Advertisement
Canada markets closed
  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CAD/USD

    0.7282
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    79.22
    +0.84 (+1.07%)
     
  • Bitcoin CAD

    85,258.79
    -1,462.70 (-1.69%)
     
  • CMC Crypto 200

    1,322.44
    +27.77 (+2.14%)
     
  • GOLD FUTURES

    2,316.90
    -7.30 (-0.31%)
     
  • RUSSELL 2000

    2,055.62
    -9.03 (-0.44%)
     
  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     
  • NASDAQ

    16,302.76
    -29.80 (-0.18%)
     
  • VOLATILITY

    12.96
    -0.27 (-2.04%)
     
  • FTSE

    8,354.05
    +40.38 (+0.49%)
     
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • CAD/EUR

    0.6774
    +0.0003 (+0.04%)
     

United Therapeutics: Recent Developments and Analysts’ Ratings

United Therapeutics: Recent Developments and Analysts’ Ratings

On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.